Oncology Ventures
Oncology Ventures is a venture capital firm founded in 2021 that invests in commercially validated healthcare data startups transforming U.S. cancer care delivery, with $94M in cumulative fund commitments anchored by major oncology institutions.
- Company typePrivate
- Founded2021
- HeadquartersNew York, United States
- Headcount1–10
- GTM typeB2B
- OfferingServices
What Oncology Ventures does
Oncology Ventures is a venture capital firm founded in 2021 by Ben Freeberg, a Stage 3a testicular cancer survivor, that invests in commercially validated healthcare data companies addressing fragmentation in U.S. cancer care. The firm targets startups across the oncology value chain, including early detection (mPATH, Gabbi), patient navigation and care coordination (CancerNavigator, OncoveryCare, Reimagine Care, Daymark Health), AI-powered treatment optimization and clinical workflow (Triomics, RISA Labs, Lumonus, Concr), specialty care delivery (Tono, NexCure for CAR-T in outpatient settings), research infrastructure (Ignite, SpotDoc), and precision oncology intelligence (BIOMAKERS). The fund's core technology is its investment thesis and LP network rather than a software product; the firm's primary "product" is capital, sector expertise, and distribution access to a network of cancer care institutions.
The firm operates a traditional venture fund revenue model, earning management fees and carried interest from limited partners. Fund I closed at $32 million in 2024 and Fund II closed oversubscribed at $62 million in April 2026, anchored by Texas Oncology, with limited partners collectively treating approximately one in three U.S. cancer patients. The team is lean (4 people) and includes the founder, a CFO, an executive assistant, and a venture associate sourced from Memorial Sloan Kettering and Flatiron Health. GTM is relationship-driven, with deal flow originating from the LP network, founder's personal network from his cancer journey, prior Optum Ventures and Thyme Care relationships, and earned media in healthcare/tech publications. The fund does not sell to end customers directly; portfolio companies' enterprise solutions are distributed through health systems, cancer centers, and life sciences organizations.
Oncology Ventures firmographics
Firmographics- Name
- Oncology Ventures
- Legal name
- Oncology Ventures
- Website
- https://oncology.ventures
- Company type
- Private
- Founded year
- 2021
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- Oncology Ventures is a venture capital firm founded in 2021 that invests in commercially validated healthcare data startups transforming U.S. cancer care delivery, with $94M in cumulative fund commitments anchored by major oncology institutions.
- Ownership category
- akta.pro rank
Oncology Ventures industry classification
Industry- Product category
- Venture Capital / Healthcare Investment
- NAICS
- Portfolio Management and Investment Advice (523940)
- SIC
- Investment Advice (6282)
- akta.pro primary industry
- Oncology Pathways & Precision Medicine Decision Support (HLACAGAH)
- akta.pro secondary industry
- Oncology & Cancer Specialty Hospitals (HLAFAHAC)
Keywords
Where Oncology Ventures is headquartered
LocationHeadquarters
- HQ city
- New York
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Oncology Ventures business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Marketing or Sales, Technology or R&D
Revenue model
- Fund Management / Carry: Oncology Ventures generates returns through venture fund management, collecting management fees and carried interest from successful portfolio company exits. Fund II is a $62M oversubscribed fund nearly doubling the $32M Fund I.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels3 records
Oncology Ventures product offering
Product offeringCore offering
Oncology Ventures is a venture capital firm that invests in commercially validated, data-driven healthcare startups addressing the biggest problems in cancer care. The firm manages dedicated oncology-focused funds (Fund I at $32M and Fund II at $62M) backed by institutional limited partners that include major U.S. cancer care institutions such as Texas Oncology, Moffitt Cancer Center, City of Hope, Fred Hutch Cancer Center, Atlantic Health, and Cardinal Health. The firm targets startups across early detection, patient navigation, AI-powered treatment optimization, value-based care delivery, and clinical workflow automation.
Differentiator
Problem solved
Functional benefit
Products and services
- Oncology Ventures Fund I
- Oncology Ventures Fund II
Quantifiable outcome
- Fund II at $62M oversubscribed, nearly doubling Fund I ($32M) and exceeding $50M target
- +2 more outcomes
Companies that use Oncology Ventures
Customer profileSegments1 record
Ideal customer profiles2 records
Oncology Ventures technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Oncology Ventures partnerships and signals
Strategic signalPartnerships
Two partnerships are on record, tiered core.
- Daymark HealthcoreOncology Ventures promotes Daymark Health's value-based oncology care model at conferences alongside the fund. Daymark Health raised $20M Series A to scale tech-enabled cancer care platform across the U.S.
- CancerNavigatorcoreOncology Ventures announced investment in CancerNavigator, a platform combining real-time claims detection, evidence-based research engine mapping over 200,000 cancer-specific scenarios, and national provider suitability database to improve oncology routing decisions. One million Americans now have access through their health plans.
Scale indicators7 records
Recent moves7 records
Expansion highlights5 records
Oncology Ventures competitors and assessment
Company assessmentBroad incumbents
- Khosla Ventures: Large venture firm with significant healthtech and biotech exposure, including AI-driven diagnostics and digital health. Comparable as a healthcare-active investor with much broader sector mandate than Oncology Ventures' specialist focus.
- Andreessen Horowitz (a16z Bio + Health): Major venture firm with dedicated Bio + Health fund investing across digital health, biotech, and care delivery. Comparable as a healthcare-active investor but operating at mega-fund scale and broader thesis than an oncology-focused specialist.
- General Catalyst: Large multi-stage venture firm with a significant healthcare practice (Health Assurance), investing across digital health, biotech, and care delivery. Comparable as a major healthcare investor but at much larger scale and broader mandate than Oncology Ventures.
- Lux Capital: Science and technology-focused venture firm with deep exposure to healthtech, biology, and frontier science including oncology-adjacent companies. Comparable as a thesis-led investor but with a broader science mandate than pure oncology focus.
- GV (Google Ventures): Alphabet's venture arm with active life sciences and digital health practice, including oncology investments. Comparable as a tech-forward healthcare investor but with a much broader sector mandate than Oncology Ventures.
Direct peers
- ARCH Venture Partners: Early-stage venture firm specializing in life sciences, biotechnology, and healthcare technology, with significant oncology exposure. Comparable as a deep, science-driven healthtech specialist.
- Frist Cressey Ventures: Healthcare-focused venture firm that co-led Modicus Prime's round alongside Oncology Ventures. Highly comparable as a thesis-driven investor in healthcare technology and services, with similar LP base among provider systems.
- Section 32: Venture fund founded by Bill Maris (formerly Google Ventures) investing at the intersection of technology and biology, including oncology and AI-driven healthcare. Highly comparable as a thesis-driven, oncology-and-healthtech-focused specialist investor.
- Foresite Capital: Healthcare and life sciences-focused venture firm backing data, diagnostics, and therapeutic companies. Comparable as a specialist investor with deep domain focus on healthcare innovation including oncology.
- Optum Ventures: Healthcare-focused venture arm of Optum/UnitedHealth Group that invests in data and technology companies transforming care delivery. Most directly comparable given founder Ben Freeberg's prior investing role there and shared thesis around healthcare data infrastructure.
Market position
Strengths5 records
Weaknesses4 records
Competitive moat4 records
Key risks5 records
Key highlights6 records
Customer concentration
Oncology Ventures social profiles
Digital presenceOncology Ventures financial estimates
Financial estimateRevenue estimate
Valuation estimate
Oncology Ventures leadership team
Management profileNumber of profiles
Profiles4 records
Oncology Ventures funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Oncology Ventures M&A and investment
M&A and investmentM&A
Investments17 records
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Oncology Ventures
What does Oncology Ventures do?
Oncology Ventures is a venture capital firm that invests in commercially validated, data-driven healthcare startups addressing the biggest problems in cancer care. The firm manages dedicated oncology-focused funds (Fund I at $32M and Fund II at $62M) backed by institutional limited partners that include major U.S. cancer care institutions such as Texas Oncology, Moffitt Cancer Center, City of Hope, Fred Hutch Cancer Center, Atlantic Health, and Cardinal Health. The firm targets startups across early detection, patient navigation, AI-powered treatment optimization, value-based care delivery, and clinical workflow automation.
Is Oncology Ventures a public or private company?
Oncology Ventures is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was Oncology Ventures founded?
Oncology Ventures was founded in 2021. It employs 1 to 10 people.
Where is Oncology Ventures based?
Oncology Ventures is headquartered in New York, United States, in the North America region.
How does Oncology Ventures make money?
One revenue line is on record: fund Management / Carry.
Who are Oncology Ventures's main competitors?
Broad incumbents on record are Khosla Ventures, Andreessen Horowitz (a16z Bio + Health), General Catalyst, Lux Capital and GV (Google Ventures). Direct peers are ARCH Venture Partners, Frist Cressey Ventures, Section 32, Foresite Capital and Optum Ventures.
Does Oncology Ventures have an API?
No public API is recorded for Oncology Ventures.
What industry is Oncology Ventures in?
Oncology Ventures's product category is Venture Capital / Healthcare Investment. Its primary akta.pro industry code is HLACAGAH, Oncology Pathways & Precision Medicine Decision Support, with a secondary code of HLAFAHAC, Oncology & Cancer Specialty Hospitals. Its NAICS code is 523940 and its SIC code is 6282.